Bortezomib inhibits mTOR pathway in multiple myeloma cells via induced expression of REDD1.

ABSTRACT: The combination of bortezomib and dexamethasone should become the reference induction treatment for multiple myeloma patients younger than 65 years. Pharmacogenomic profiles of genes involved in response to treatment may help to understand resistance. We performed gene expression profiling in 9 myeloma cell lines, incubated or not with bortezomib and dexamethasone for 6 hours. Supervised analysis identified significantly up regulated genes involved in stress responses. We focused on REDD1 a gene known to be rapidly induced by a wide variety of stress conditions and DNA damages. REDD1 expression was early and highly induced after bortezomib exposure. REDD1 induction was associated with the dephosphorylation of P70 S6 ribosomal kinase (P70S6K), a key substrate of mTOR. These effects were de

ORGANISM(S): Homo sapiens

SUBMITTER: Wilfried Gouraud 

PROVIDER: E-GEOD-11866 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress